tortois hare
nexsi thesi still intact commentari
suggest prudent approach contract
time fundament view remain unchang remain
overweight pt
quarter deliv plasma weak teg appear time relat
haemonet report top-line revenu vs mse plasma
revenu line estim weak
blood center vs mse hemostasi vs mse led top-line miss
plasma growth solid unit placement strong
system fleet convert nexsi teg weak primarili
result order time ep estim primarili
driven lower tax rate pleas see exhibit reconcili result vs
mse central question quarter stock weak reflect concern
plasma time revenu delv
concern structur remain confid issu time
haemonet share fell concern larg custom contract time
impact guidanc system place quarter sinc
last earn call nexsi placement beyond system may stall
book contract grifol estim
constitut system instal base
provid guidanc report earn may manag
guid contract yet confirm street estim like
move lower contribut csl/grifol contract remov
reset expect never welcom action derisk buy
time manag creat valu nexsi system
nexsi thesi still intact overweight thesi base
expect compani could exceed long rang plan lrp
nexsi price cost save complex reduct
initi fundament outlook two item chang
appreci may connect time delay lower system valu
view support exist fraction dilig last year
underli plasma market growth outlook move
medic technolog unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
start lrp least de-risk lrp target
heighten need effici collect nexsi platform
clinic dilig remain posit yield throughput workflow
manag commentari real-world outcom actual bullish
today month ago analysi plasma busi last
quarter adjust nexsi util indic compani receiv valu
commensur assumpt premium rang manag
remain confid abil doubl ebit quadrupl
number remain larg unchang
risk adjust base time fundament view unchang
take prudent approach grifol estim
push contribut contract competit captur
valu remain focu manag expect patient given
market acceler real-world outcom side above-
consensu top-line estim come plasma growth
estim come reflect market growth pt price
contribut assum haemonet averag system instal base increas
system sinc repres instal base
price premium could suggest pt growth contribut model
csl/grifol contract come on-line start model
plasma growth model chang pure time perspect
derisk expect continu see nexsi valu proposit
intact see anoth inflect year
earn growth look like elimin csl/grifol
model impact earn growth ep estim move
reflect y/i ep subject upsid csl/grifol contract
commun around spend reinvest lead us model flat sg
margin initi price benefit lead us model bp
gross margin expans primari driver y/i leverag still
model ebit vs call lrp
fundament view exceed lrp target
chang remain convinc valu proposit nexsi
remain overweight pt still see guidanc achiev
comfort top end manag measur commentari
disappoint investor mean number like
come confid nexsi remain primari
driver overweight thesi addit lever
deploy beyond nexsi includ teg file trauma indic
line prior timelin oper leverag via tuck-in
balanc sheet deploy continu see path exceed
compani lrp chang model base interim time
versu fundament chang thesi view nexsi
ep estim come ep estim remain larg
unchang price target come continu reflect
ebitda estim includ quarter contribut
premium smid cap peer see exhibit given faster growth remain
haemonet nexsi drive transform stori
haemonet nexsi drive transform stori
stori tie long-
price target reflect ev/ebitda
estim premium smid cap peer
upsid nexsi price complex reduct initi dropthrough
balanc sheet option drive ebit achiev
per liter increment plasma price nexsi greater cost
save drop balanc sheet option third parti financ
capit deploy drive materi upsid ebit
nexsi complex reduct initi drive ebit
haemonet abl achiev per liter increment plasma price
nexsi save help compani exceed lrp ebit object
nexsi unabl gain materi price benefit nexsi unabl
creat materi valu custom and/or unabl obtain
competit price plasma growth remain line market growth rate
minim cost save drop
rang plan lrp doubl oper incom
quadrupl turnaround
primarili lever nexsi product
compani next-gener plasma
valu creation materi yield
opportun appreci see
posit backdrop nexsi drive
valu per liter plasma
custom expect share
profit increment per
liter price indic nexsi alon
drive lrp object
complex reduct initi
seek provid cost save
add option de-risk
lrp believ allow haemonet
exceed lrp object
nexsi valu price potenti
drop-through
risk achiev price
benefit nexsi ii identif
addit cost opportun iii capit
downsid risk includ nexsi
disappoint ii cost save fail materi
iii blood bank slow materi iv
million except ep
dollar million except per share data
good sold
dollar million except per share data
dollar million except per share data
equival
accum comprehens incom
dollar million except per share data
loss asset dispos
chang work capit
net provid oper activ
capit intang asset
sale properti invest
net use invest activ
chang equiti
net financ activ
net chang
equival bop
equival eop
